Prehospital TXA After PATCH-Trauma: Who Should Get It?

Prehospital TXA After PATCH-Trauma: Who Should Get It?

By Chester "Chet" Shermer, MD, FACEP  •  2026-09-09  •  9 min read  •  Pharmacology

At 02:10, a patient with a deep pelvic wound is pale, fast, and getting colder. The blood pressure is not yet dramatic. Your crew has a pressure dressing, an IV, a trauma center on the radio, and a medication question: should this patient receive tranexamic acid (TXA) now?

The modern answer is not “give TXA to every trauma patient.” The answer is to identify adult trauma patients with clinical signs of hemorrhagic shock, give TXA early when it fits your local protocol, and never let the medication delay hemorrhage control, resuscitation, or transport. The 2025 joint guidance from NAEMSP, ACEP, and ACS-COT reflects a field that has moved past both reflexive enthusiasm and reflexive rejection.

The lesson from PATCH-Trauma

TXA slows fibrinolysis, the process that breaks down formed clots. The original CRASH-2 trial enrolled more than 20,000 adults with significant bleeding or risk of significant bleeding and found lower 28-day mortality with TXA than with placebo. Its timing analysis found the clearest benefit when treatment started within the first hour, with benefit still present from one to three hours; treatment after three hours was not beneficial and may have been harmful. (CRASH-2; CRASH-2 timing analysis)

That result drove widespread adoption. Then PATCH-Trauma tested a more specific question in advanced trauma systems: would prehospital TXA followed by an eight-hour infusion improve six-month survival with favorable functional outcome in adults with major trauma and suspected trauma-induced coagulopathy? It did not. Favorable functional outcome occurred in 53.7% of the TXA group and 53.5% of the placebo group. Six-month mortality was numerically lower with TXA, but the difference did not reach statistical significance. Serious adverse events, including vascular occlusive events, did not differ meaningfully. (PATCH-Trauma)

PATCH-Trauma does not prove that TXA has no place in EMS. It does change the claim: TXA is not a universal trauma drug, and an early mortality signal does not guarantee better later function. The 2025 joint statement describes contradictory evidence while allowing TXA for selected adults with hemorrhagic shock. (2025 NAEMSP/ACEP/ACS-COT position statement)

What current guidance says

The 2025 NAEMSP, ACEP, and ACS-COT guidance says prehospital TXA may reduce mortality in adult trauma patients with hemorrhagic shock when given after lifesaving interventions. It says the medication appears safe, with low reported risk of thromboembolic events or seizure, but it also says that the best dose, rate, and route have not been established. (Joint position statement and resource document)

That is a useful protocol position because it gives a target population. The patient should have clinical signs of hemorrhagic shock, not simply a traumatic mechanism or a frightening wound. The guidance does not support routine TXA for patients without clinically significant bleeding, and it recommends administration no later than three hours after injury when a system uses TXA. (2025 joint guidance)

The same guidance describes two reasonable adult dosing strategies for civilian systems: 1 gram IV or IO followed by a hospital-based 1-gram infusion over eight hours, or 2 grams IV or IO by infusion or slow push. It does not declare one strategy superior. Your medical director, trauma partners, pharmacy team, and receiving centers need to choose one clear local pathway and make the handoff explicit. (2025 joint guidance)

Children need their own answer. The position statement says the role of prehospital TXA in pediatric trauma patients with clinical signs of hemorrhagic shock has not been studied well enough to establish standardized dosing. A pediatric protocol cannot be created by shrinking the adult dose and calling the problem solved. (2025 joint guidance)

Build the decision around the clock

The first question is time from injury. Ask the patient, family, witnesses, law enforcement, and dispatch record. Document the best estimate. If the time is unknown, say so rather than inventing precision. The early-treatment signal from CRASH-2 and the three-hour boundary in current guidance make the clock a clinical variable, not a paperwork detail. (CRASH-2 timing analysis; 2025 joint guidance)

The second question is whether hemorrhagic shock is clinically present. Look at the whole patient: mental status, skin, pulse quality, respiratory pattern, temperature, mechanism, external blood loss, suspected internal bleeding, and the trend in vital signs. A single normal blood pressure should not end the assessment, but a low blood pressure is not required by every protocol either. The receiving team needs your findings and your reasoning, not only the medication name. (2025 joint guidance)

The third question is what must happen before TXA. Direct pressure, wound packing, tourniquet use, pelvic stabilization when indicated, airway and ventilation support, warming, blood products when available, and rapid transport remain the work that changes the first minutes of care. TXA is an adjunct. The joint guidance specifically places it after lifesaving interventions and says it should not delay care. (2025 joint guidance)

This is where a simulation case earns its keep. Have the team verbalize the injury time, shock evidence, life threats, dose pathway, and receiving-center plan while the scene is noisy. A short practice case on EMS-MedSim can make the sequence familiar. Teams that train with EM-Sim can apply the same principle to physician handoff and resuscitation decisions. The medication is easy to memorize; the decision under pressure is the skill.

Make the dose and handoff boring

A protocol should force five items into the record: estimated injury time, evidence of hemorrhagic shock, life-saving interventions already completed, TXA dose and route, and time of administration. Include whether the patient received TXA before your crew arrived. The joint statement recommends clear communication to prevent duplicate administration and to support appropriate monitoring at the receiving facility. (2025 joint guidance)

That approach fits the wider mission of Global MedOps Command: turn clinical knowledge into repeatable decisions that hold up when the scene is loud and the data are incomplete. For military and austere trauma teams, MilMedSim is a natural companion for practicing early hemorrhage decisions without confusing military protocol with a civilian EMS standing order.

Dr. Chet's Take

I have watched trauma care change across 25 years in emergency medicine, HEMS, critical care transport, and Army National Guard medical command. TXA is a good example of why clinicians need to keep reading after a drug becomes familiar. Early evidence made the medication feel like a simple answer. PATCH-Trauma made the answer less comfortable. The right response is not to throw out the drug or to defend it as a reflex. The right response is to use it for the patient your protocol actually describes.

That being said, I do not want a paramedic spending the first minutes of a hemorrhaging patient arguing with a syringe. Control the bleeding. Support the airway and breathing. Keep the patient warm. Move toward definitive care. Then give TXA when the injury clock and the clinical picture support it. I have taken handoffs where the medication was announced but the reason for it was missing. That is not a complete handoff. A dose without a decision is just a number.

If you are running this call, make your crew say five things out loud: injury time, shock findings, life threats handled, dose and route, and what the receiving team needs to know. If your agency cannot answer those five questions, the protocol needs work before the next difficult trauma call. Clear decisions beat confident habits.

Key Takeaways

FAQ

Should EMS give tranexamic acid to every trauma patient?

No. Current joint guidance limits consideration to adult trauma patients with clinical signs of hemorrhagic shock after lifesaving interventions, with administration no later than three hours after injury when TXA is used. (2025 joint guidance)

What did the PATCH-Trauma trial show about prehospital TXA?

PATCH-Trauma found no difference in six-month survival with favorable functional outcome between prehospital TXA and placebo in adults with major trauma and suspected trauma-induced coagulopathy. Serious adverse events did not differ meaningfully. (PATCH-Trauma)

What dose of TXA should EMS use for adult trauma?

The 2025 joint guidance describes either 1 gram IV/IO followed by a hospital-based 1-gram infusion over eight hours or 2 grams IV/IO by infusion or slow push. The best strategy remains unsettled, so follow the medical director-approved local protocol. (2025 joint guidance)

If you're a EMT, paramedic, flight medic, CCTP, or EMS medical director trying to understand how AI will actually impact your clinical practice — not just the hype — I put together a free practical guide. You can download it here: AI in EM Survival Guide.

Sources

Related articles